Alere's $33.2m Settlement May Reflect Growing US Fed Focus On Dx
Executive Summary
Abbott subsidiary Alere is paying $33.2m to settle allegations the company knowingly allowed hospitals to bill for tests performed using unreliable diagnostics marketed by the company. It's one of the first times that US DoJ has held a company responsible for false claims filed due to faulty test results.
You may also be interested in...
Device Settlements Contribute To DoJ's $2.5Bn Health-Care FCA Haul
The US Department of Justice collected $2.8bn in settlements and judgments involving violations of the False Claims Act in 2018, including $2.5bn in health-care cases. Key device industry recoveries included $33.2m from Alere, $12.5m from Angiodynamics, and $30m in two separate settlements from Covidien and its subsidiary ev3.
Mid-Year Enforcement Roundup: Focus On Opioids, As Other Areas Lag
A recent report from law firm Gibson Dunn seems to show that the Trump administration, while aggressively pursuing opioid enforcement actions, slowed down enforcement in other areas during the first half of 2018. But important case-law developments continue.
Despite Legal Dispute, Abbott Set To Buy Alere for $5.3bn
Soon before it was set to take Alere to court in an attempt to break out of an acquisition deal, Abbott has reversed course and plans to buy the company for half a billion less than the original price tag.